+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparison of phenobarbitone and ursodeoxycholic acid in drug-augmented hepatobiliary scintigraphy for excluding the diagnosis of obstructive cholestasis in neonatal cholestasis syndrome



Comparison of phenobarbitone and ursodeoxycholic acid in drug-augmented hepatobiliary scintigraphy for excluding the diagnosis of obstructive cholestasis in neonatal cholestasis syndrome



Nuclear Medicine Communications 36(8): 827-832



Neonatal cholestasis is a common cause of jaundice among newborns. Hepatobiliary scintigraphy plays an important role in the diagnosis of neonatal cholestasis by ruling out extrahepatic biliary atresia, which is one of the common causes. Phenobarbitone and ursodeoxycholic acid (UDCA) have been used to improve the specificity of hepatobiliary scintigraphy in ruling out obstructive causes of neonatal cholestasis syndrome (NCS). The present study was undertaken to compare the utility of phenobarbitone and UDCA in augmenting hepatobiliary scintigraphy in the evaluation of NCS. Seventy-four consecutive patients with NCS referred for hepatobiliary scintigraphy were initially subjected to a baseline scan. Twenty patients showed tracer activity in the intestine within 24 h after injection, thus ruling out obstructive cholestasis. Fifty-four patients who did not show any tracer activity in the intestine were categorized as nonexcretors. Four nonexcretors were lost to follow-up and were excluded from the study. Fifty nonexcretors showing scan features suggestive of obstructive cholestasis were further randomized into those receiving phenobarbitone (n=20), UDCA (n=20), or placebo (n=10). These groups were further evaluated with drug-augmented hepatobiliary scintigraphy, after premedication, for any excretory activity in the intestine. Out of 50 patients who were evaluated with drug-augmented hepatobiliary scintigraphy two patients from the phenobarbitone group and one patient each from UDCA and placebo groups showed a change in excretory pattern from the baseline scan. However, these results were statistically nonsignificant (P=1.00). In the present study, drug-augmented (phenobarbitone or UDCA) hepatobiliary scintigraphy did not seem to improve the results (negative predictive value) for ruling out an obstructive cause of neonatal cholestasis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057470034

Download citation: RISBibTeXText

PMID: 25920049

DOI: 10.1097/mnm.0000000000000322


Related references

Drug-augmented hepatobiliary scintigraphy for evaluation of neonatal cholestasis: What does the evidence point to?. Nuclear Medicine Communications 36(9): 966, 2016

Ursodeoxycholic acid versus phenobarbital pretreatment prior to hepatobiliary scintigraphy in neonatal cholestasis: is it time for shifting gears towards a practice change?. European Journal of Nuclear Medicine and Molecular Imaging 42(7): 1160-1161, 2016

Ursodeoxycholic acid-augmented hepatobiliary scintigraphy in the evaluation of neonatal jaundice. Journal of Nuclear Medicine 45(9): 1488-1492, 2004

Findings of hepatobiliary scintigraphy and liver biopsy in Maroteaux-Lamy syndrome presenting as neonatal cholestasis. Pediatrics International 48(5): 498-500, 2006

Efficacy of hepatobiliary scintigraphy in the differential diagnosis of neonatal cholestasis and postoperative follow-up after hepatoporto-digestive anastomosis. Zeitschrift für Kinderchirurgie 43(2): 81-87, 1988

Role of Hepatobiliary Scintigraphy and Preoperative Liver Biopsy for Exclusion of Biliary Atresia in Neonatal Cholestasis Syndrome. Indian Journal of Pediatrics 84(9): 685-690, 2017

Differential diagnosis of cholestasis by non-invasive methods--comparison of cholecysto-cholangiography, ultrasonics and hepatobiliary sequential scintigraphy. Wiener Klinische Wochenschrift 95(9): 304-309, 1983

Treatment of severe cholestasis in neonatal Dubin-Johnson syndrome with ursodeoxycholic acid. Journal of Perinatal Medicine 30(2): 185-187, 2002

Neonatal cholestasis hepatobiliary scintigraphy and clinical correlates. Journal of Nuclear Medicine 27(6): 931, 1986

Hepatobiliary scintigraphy in the study of neonatal hepatic cholestasis. La Radiologia Medica 78(6): 638-644, 1989

Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard. Mmw Fortschritte der Medizin 149(21): 49, 2007

Hepatobiliary scintigraphy and the string test in the evaluation of neonatal cholestasis. Journal of Pediatric Gastroenterology and Nutrition 8(3): 292-296, 1989

Hepatobiliary scintigraphy with technetium-99m disofenin in the evaluation of neonatal cholestasis. Journal of Pediatric Gastroenterology and Nutrition 6(6): 885-891, 1987

Potential pitfalls in the evaluation of neonatal cholestasis with technetium 99m hepatobiliary scintigraphy. Journal of Nuclear Medicine 27(6): 931, 1986

Diagnostic utility of hepatobiliary scintigraphy with 99mTc-DISIDA in neonatal cholestasis. Journal of Pediatrics 110(6): 855-861, 1987